Invention Grant
- Patent Title: TDO2 Inhibitors
-
Application No.: US16065397Application Date: 2016-12-23
-
Publication No.: US10800780B2Publication Date: 2020-10-13
- Inventor: Xingyu Lin , Po-wai Yuen , Rohan Mendonca , Brendan Parr , Richard Pastor , Zhonghua Pei , Lewis Gazzard , Firoz Jaipuri , Sanjeev Kumar , Xiaokai Li , Roheeth Pavana , Hima Potturi , Venkata Velvadapu , Jesse Waldo , Zuhui Zhang , Guosheng Wu , Benjamin Douglas Sellers
- Applicant: Genentech, Inc. , NewLink Genetics Corporation
- Applicant Address: US CA South San Francisco US IA Ames
- Assignee: Genentech, Inc.,NewLink Genetics Corporation
- Current Assignee: Genentech, Inc.,NewLink Genetics Corporation
- Current Assignee Address: US CA South San Francisco US IA Ames
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@4af5a44 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@2b20ebd4 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@139749b5
- International Application: PCT/CN2016/111730 WO 20161223
- International Announcement: WO2017/107979 WO 20170629
- Main IPC: A61K31/4188
- IPC: A61K31/4188 ; A61K31/407 ; A61K31/4035 ; C07D487/04 ; C07D519/00 ; A61P35/00 ; A61K45/06 ; A61K38/16
Abstract:
Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
Public/Granted literature
- US20190016726A1 TDO2 Inhibitors Public/Granted day:2019-01-17
Information query
IPC分类:
